Glatiramer acetate treatment negatively regulates type I interferon signaling

OBJECTIVE: Glatiramer acetate (GA; Copaxone), a disease-modifying therapy for multiple sclerosis (MS), promotes development of anti-inflammatory (M2, type II) monocytes that can direct differentiation of regulatory T cells. We investigated the innate immune signaling pathways that participate in GA-...

Descripción completa

Detalles Bibliográficos
Autores principales: Molnarfi, Nicolas, Prod'homme, Thomas, Schulze-Topphoff, Ulf, Spencer, Collin M., Weber, Martin S., Patarroyo, Juan C., Lalive, Patrice H., Zamvil, Scott S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645172/
https://www.ncbi.nlm.nih.gov/pubmed/26601118
http://dx.doi.org/10.1212/NXI.0000000000000179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645172/
https://www.ncbi.nlm.nih.gov/pubmed/26601118
http://dx.doi.org/10.1212/NXI.0000000000000179

Ejemplares similares